Abstract

BackgroundB cell depletion therapy based on rituximab (RTX) is an effective therapy for Rheumatoid Arthritis (RA) and other autoimmune diseases such as Thrombotic Thrombocytopenic Purpura (TTP). Serum BAFF levels are...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Evidence of persistent neurologic injury following thrombotic thrombocytopenic purpura
Leslie Witkoff ... Paul Maruff
American Journal of Hematology | VOL. 86
Leslie Witkoff, et. al.Leslie Witkoff ... Paul Maruff
27 Oct 2010
Increased serum levels of transforming growth factor beta-1 in patients affected by thrombotic thrombocytopenic purpura (TTP): its implications on bone marrow haematopoiesis.
Luigi Gugliotta ... Paola Borgatti
British journal of haematology | VOL. 84
Luigi Gugliotta, et. al.Luigi Gugliotta ... Paola Borgatti
01 Jul 1993
A8.14 Effect of rituximab on B-cell phenotypes and on B-cell activating factor receptor expression in patients with thrombotic thrombocytopenic purpura
Elena Becerra ... Geraldine Cambridge
Annals of the Rheumatic Diseases | VOL. 73
Elena Becerra, et. al.Elena Becerra ... Geraldine Cambridge
31 Jan 2014
Deficiency of ADAMTS-13 in thrombotic and thrombocytopenic purpura
G Remuzzi
Journal of Thrombosis and Haemostasis | VOL. 1
G RemuzziG Remuzzi
01 Sep 2003
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers